3′-18F-Fluoro-3′-Deoxy-l-Thymidine: A New Tracer for Staging Metastatic Melanoma?

摘要: In this study, the feasibility of 3'-F-18-fluoro-3'-deoxy-L-thymidine PET (F-18-FLT PET) for staging patients with clinical stage III melanoma was investigated. Methods: Ten and metastases to locoregional draining lymph nodes, III-based on physical examination, chest radiography, lactate dehydrogenase, histopathologic confirmation-underwent a whole-body F-18-FLT scan 1 h after injection median 400-MBq dose (range, 185-430 MBq) F-18-FLT. All lesions were verified using American Joint Committee Cancer Staging System, which includes spiral CT, ultrasound, examinations. Size mitotic rate metastatic nodes skin metastases; determined. Results: samples 18F-FLT categorized over anatomic regions correlated. correctly visualized by PET. Region-based sensitivity detection node disease 88%. There 3 true-negative 2 false-positive lesions. The limit appeared be approximately 6 mm or 9 mitoses per mm(2). Two upstaged PET, confirmed CT. patients, detected total additional therapeutic consequences, without influencing staging. These initially missed Conclusion: seems promising (re)staging purposes in melanoma. Further research is needed, should compared F-18-FDG